Please check the below announcement for our next NCI Technology Webinar, on April 24^th from 11am-12pm.  This webinar features a new family of Proteolysis Targeting Chimeras (PROTACS) that selectively target Proviral Integration for the Moloney murine leukemia virus (PIM) kinases. PIM kinases play a role in cancer development and mediating resistance to radio and chemotherapy and are overexpressed in multiple cancers. Several small molecule PIM kinase inhibitors have had minimal effect in suppressing cancer phenotypes due to the PIM kinase inhibitors promoting intrinsic resistance. By contrast, these PIM-targeted PROTACs suppress PIM kinase activity by completely degrading the PIM kinase proteins thus avoiding intrinsic resistance. Additionally, these PROTACs prevent the onset of resistance due to increased expression of PIM kinases that occur from catalytic inhibition. Therefore, these PROTACs represent unique opportunities as novel anti-cancer therapies.

 

The NCI is looking for a commercialization partner for this technology.

※ 해당 세미나는 사전 등록자에 한해 녹화영상이 제공됩니다.   

※ 등록 바로가기